10 June 2019 | News
SBF Healthcare has signed MoUs with US universities for ongoing neuro-oncology research
Wg Cdr (Dr) V G Vasishta
For the first time in Indian history, Sequentially Programmed Magnetic field (SPMF) Therapy invented by Wg Cdr (Dr) V G Vasishta, Founder & Chairman, SBF Healthcare, has set its benchmark in medical technology and has been recently adopted by the US for neuro-oncology research for treatment of malignant brain tumor cancer.
Memorandums of Understanding (MoU) have also been signed between SBF Healthcare and University of California, Los Angeles (UCLA) and University of Pennsylvania for advancement in neuro-oncology research for treatment of malignant brain tumor cancer.
In India, at least 40000-50000 people are diagnosed with Glioblastoma Multiforme (GBM) brain tumors. Brain tumors are primarily treated with surgery, chemotherapy and radiation. After these treatments, the average survival is not more than 14 months. However, with SPMF therapy, the survival rate for patients increases for more than five years on an average.
The patient's condition is evaluated using MRI and the Karnofsky Performance Score (KPS) which are the gold standards for evaluating the efficacy of a therapy. This treatment is administered through an advanced medical device called AKTIS SOMA. This device has been manufactured at the R&D centre of SBF Healthcare.
A typical treatment of surgery, chemotherapy and radiation costs around $200,000 for brain tumor patients. With SPMF therapy, the treatment cost drops down to approximately $3000.
This therapy is conducted over a 28-days period, one hour per day. Besides brain tumor, this therapy has also been successful in treating osteoarthritis.
Dr Vasishta is also looking into using this therapy for treating diabetes and Alzheimer's in the coming years. Trials for diabetes treatment have already been approved by the Indian Council of Medical Research (ICMR).